1. Distinct clusters exist within polycythemia vera, essential thrombocythemia and myelofibrosis.
2. Clusters are not direct surrogates for current prognostic scores. For physicians, assessing and treating the symptom burden represents one of the most challenging features of managing MPNs due to the paucity of effective treatment regimens and marked heterogeneity between patient presentations. In 2007, our group published the results of a cross-sectional survey of 1,179 MPN patients which helped assess and quantify that these patients do indeed suffer from excessive fatigue compared to age-matched controls and that symptoms compromise social functioning, physical activity, independence in daily tasks, and global quality of life.
1 Additionally, this survey found that traditional therapies including hydroxyurea, interferon, thalidomide, corticosteroids, androgens, and erythropoietin analogues were suboptimal in reducing symptoms.
For personal use only. Figure A2 ) and semipartial r-squared while maintaining individual cluster sizes to be at least 5% of the sample in hierarchical clustering using Ward linkage. In order to be included in the cluster analysis, patients needed to complete all 19 questions in the survey.
Thus, 1,470 out of 1,885 patients in the database were included. Final cluster assignment within disease was based on the nonhierarchical k-means method using the number of clusters identified via the previous hierarchical clustering procedure. Split-half validation was used to examine internal validity of the final cluster results. 11, 12 In split-half validation within each disease group, cluster assignment is performed in a randomly selected pair of split-half subsamples, and the Euclidean distance between each subject's symptom scores and the mean symptom scores for that patient's cluster is compared between split-half subsamples using a Kruskal-Wallis test (the size of the difference is described Table A1 ).
Cluster Overview:
Among all participants, five symptom clusters were identified. Distribution of age and gender, along with language, laboratory abnormality (anemia), and prior hemorrhage differed significantly across clusters (p<0.05, Table 1 and A1).
MPN-SAF TSS also significantly differed across clusters (P<0.001, Figure 1A ). A heatmap (visual representation of individual symptom levels across patients ordered by cluster) is presented in Figure 2A (also see Figure A2 for mean symptom scores by cluster). IPSET risk scores did not significantly differ across 
Cluster 2: Moderate-I ET (n=97, 16%
). This cluster was typified by the predominant complaint of sexual dysfunction (mean 7.6) out of proportion to other symptoms (all means ≤ 2.6 other than fatigue, mean 3.3). These patients had the second-to-lowest overall MPN-SAF TSS. The majority of patients (62.7%) had disease duration less than 3 years. Subjects in this group were predominantly female (61.7%) and had Intermediate risk (54.9%). This cluster had the highest prevalence of anemia (36.3%). Patients also had the lowest rate of prior thrombosis (17.5%). (Table A2 ) including anemia (21%), leukopenia (4%) and thrombocytopenia (8%).
Cluster 3: Moderate-II ET (n=155, 25%).

Cluster Overview:
Five clusters were identified. Distribution of gender, language, laboratory abnormalities, spleen size, and leukopenia varied significantly across clusters (p<0.05, Table 1 Subjects were mostly male (58.9%). Most patients were in the Low (36.5%) or Intermediate-1 (34%) risk category. This cluster also had the lowest number of patients with a laboratory abnormality (21.3%) including anemia (15.8%) and leukopenia (1.5%). These patients also had the smallest spleen size (mean 1.7 cm) and the lowest rate of prior hemorrhage (4.3%) of all clusters.
Cluster 2: Moderate-1 PV (n=118, 23%). This cluster was typified by the predominant complaint of sexual dysfunction (mean 7.2) following by fatigue (mean 4.7) and insomnia (mean 3.6) with the second to lowest mean MPN-SAF TSS. The majority of patients (62.5%) had disease duration of 3 years or more.
Subjects in this cluster were predominantly male (65.8%) and were equitably dispersed among PV risk categories of Low (32.6%), Intermediate-1 (34.9%) and Intermediate-2 (30.2%) risk. This cluster had the largest percentage of patients with a laboratory abnormality (41.9%) including anemia (29.1%), thrombocytopenia (11.6%) and leukopenia (10.5%). They also had the highest percentage of patients with a prior splenectomy (1.6%).
Cluster 3: Moderate-2 PV (n=62, 12%). This cluster was characterized by
high MPN-SAF scores in cytokine-related symptoms including fatigue (mean 6.9) and pruritus (mean 6.9). The majority of patients (68.4%) had a disease duration of 3 years or more. Patients in this cluster were of equal gender distribution (48.4% male) and the majority of patients were in the Low PV risk category 
Intermediate-1 (45.5%). No patients had thrombocytopenia but the cluster did demonstrate the highest rate of prior thrombosis (34.8%). The rate of anemia was 27.3%.
MF Symptom Clusters
Subject Demographic and Disease Characteristics:
Data from 329 prospectively enrolled persons with MF was collected 
Cluster Overview:
Among all participants, four symptom clusters were identified. Among clusters, disease features including leukopenia, thrombocytopenia and enlarged spleen varied significantly among clusters (p<0.05, Table 1 and A3). MPN-SAF TSS varied significantly among clusters (p<0.001; Figure 1C ). Heatmap showing variability of symptoms across clusters is presented in Figure 2C (also see Figure   A2 
Cluster 2: Moderate-I MF (n=105, 32% [65% PMF, 20% post-ET MF, 15% post-PV MF]). Cluster 2 was the second largest cluster. Patients had the longest
MF disease duration of all clusters (mean 6.7 years) with 50% having disease duration under 3 years. The majority of patients in this cluster were DIPSS Intermediate-1 risk (54.2%), followed by Intermediate-2 risk (23.7%). Subjects had a moderate rate of lab abnormalities (67.4%; anemia, 56.2%; thrombocytopenia 34.5%) but high severity of fatigue (mean 6.1), sexual For personal use only. on July 15, 2017. by guest www.bloodjournal.org From dysfunction (mean 6.0), sad mood (mean 4.1), and inactivity (mean 4.0).
Transfusion dependency was present in 21% of the sample and this cluster also had the largest spleen size (mean 8.7 cm below the left costal margin). among the clusters. Additionally, individuals in this cluster had the lowest rate of leukopenia (7.9%), the second smallest spleen size (mean 7 cm) and the second lowest rate of prior thrombosis (9.6%), prior hemorrhage (7.8%) and requirement for red blood cell transfusions (21.2%). No patients had a history of splenectomy.
Cluster 4: High MF (n=21; 6% [81% PMF, 14% post-ET MF, 5% post-PV MF])
. Cluster 4 was the most symptomatic cohort with the highest proportion of subjects with PMF. Mean MF disease duration was higher than most clusters (6.5 years), but less than that observed in Cluster 2. This cluster had the highest percentage of DIPSS High risk patients (33.3%) and no patients were Low risk.
This cluster had lower levels of end-organ complaints including abdominal pain However, the question of whether the heterogeneity observed in each MPN subtype was attributable to the existence of unique symptom clusters remained unknown. This study represents the first examination of these differences in symptom burden by cluster analysis.
As previously described, significant heterogeneity was observed both between and within MPN subtypes and likely originates from variances in For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
25.
